Paclitaxel, Carboplatin and Gemcitabine Combination as Induction Chemotherapy for Stage IIIA N2 Bulky Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|69|4|295-300

ISSN： 0030-2414

Source： Oncology, Vol.69, Iss.4, 2005-12, pp. : 295-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and Paclitaxel

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 169-174

Karger

Access to resources Recommend Favorite

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 382-390

Karger

Access to resources Recommend Favorite

Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer (Stage IIIb or IV) with a Higher T Stage (> T2)

By  

Oncology, Vol. 63, Iss. 2, 2002-09 ,pp. : 173-179

Karger

Access to resources Recommend Favorite

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2253-2261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Chemotherapy with Nab-Paclitaxel in a Heavily Treated Non-Small Cell Lung Cancer Patient: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-06 ,pp. : 401-406

Karger

Access to resources Recommend Favorite